MCID: HYP065
MIFTS: 50

Hyperaldosteronism malady

Categories: Endocrine diseases, Rare diseases, Genetic diseases

Aliases & Classifications for Hyperaldosteronism

Aliases & Descriptions for Hyperaldosteronism:

Name: Hyperaldosteronism 12 29 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:446
ICD10 33 E26 E26.9
ICD9CM 35 255.1 255.10
MeSH 42 D006929
NCIt 47 C113213
UMLS 69 C0020428

Summaries for Hyperaldosteronism

Disease Ontology : 12 An adrenal gland hyperfunction disease that results in the overproduction of aldosterone by the adrenal glands.

MalaCards based summary : Hyperaldosteronism is related to hyperaldosteronism, familial, type iii and pheochromocytoma. An important gene associated with Hyperaldosteronism is CYP11B2 (Cytochrome P450 Family 11 Subfamily B Member 2), and among its related pathways/superpathways are Peptide hormone metabolism and Renin secretion. The drugs Dopamine and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, testes and kidney, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 71 Hyperaldosteronism, also aldosteronism, is a medical condition wherein too much aldosterone is produced... more...

Related Diseases for Hyperaldosteronism

Diseases in the Hyperaldosteronism family:

Hyperaldosteronism, Familial, Type Ii Hyperaldosteronism, Familial, Type Iii
Hyperaldosteronism, Familial, Type Iv Familial Hyperaldosteronism

Diseases related to Hyperaldosteronism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 171)
id Related Disease Score Top Affiliating Genes
1 hyperaldosteronism, familial, type iii 33.9 NR3C2 REN
2 pheochromocytoma 29.8 MEN1 NPPA POMC
3 myocardial infarction 28.8 ACE AGTR1 NPPA NR3C2 REN
4 familial hyperaldosteronism 12.3
5 hyperaldosteronism, familial, type iv 12.1
6 hyperaldosteronism, familial, type ii 12.1
7 conn's syndrome 12.1
8 aldosteronism, glucocorticoid-remediable 12.0
9 liddle syndrome 11.0
10 congenital chloride diarrhea 10.8
11 hyper-reninism 10.8
12 liddle syndrome, scnn1b-related 10.7
13 liddle syndrome, scnn1g-related 10.7
14 adenoma 10.3
15 spastic ataxia 3 10.3 CYP11B1 CYP11B2
16 smith-mccort dysplasia 2 10.2 NR3C2 REN
17 shaken baby syndrome 10.2 NPPA REN
18 distal monosomy 14q 10.2 POMC REN
19 glossopharyngeal nerve neoplasm 10.2 POMC REN
20 endometrial mixed adenocarcinoma 10.2 POMC REN
21 achromatopsia 10.2 NPPA REN
22 hypotrichosis simplex 10.2 ACE REN
23 hyperinsulinemic hypoglycemia, familial, 3 10.2 ACE REN
24 carbohydrate metabolic disorder 10.2 ACE REN
25 hypothyroidism, congenital nongoitrous, 5 10.1 ACE REN
26 listeriosis 10.1 ACE REN
27 dientamoebiasis 10.1 ACE REN
28 bronchiectasis with or without elevated sweat chloride 3 10.1 CYP11B2 NR3C2 REN
29 early-onset parkinson disease 10.1 MEN1 POMC
30 congenital nystagmus 10.1 ACE REN
31 benign peritoneal mesothelioma 10.1 CYP11B1 CYP11B2 POMC
32 hemorrhagic cystitis 10.1 AGTR1 NR3C2 REN
33 preaxial polydactyly of fingers 10.1 ACE AGTR1
34 mitochondrial complex ii deficiency 10.1 MEN1 POMC
35 hypokalemia 10.1
36 inferolateral myocardial infarct 10.1 ACE NPPA
37 dystonia 25 10.1 NR3C2 REN SLC12A3
38 malignant otitis externa 10.1 POMC REN
39 cataract 21, multiple types 10.1 NR3C2 POMC REN
40 aplasia cutis congenita recessive 10.0 ACE AGTR1 CYP11B2
41 adrenal adenoma 10.0
42 cascade stomach 10.0 ACE AGTR1 REN
43 hyperuricemic nephropathy, familial juvenile 2 10.0 ACE AGTR1 REN
44 eye degenerative disease 10.0 ACE AGTR1
45 flat umbilicus familial 10.0 ACE AGTR1 REN
46 rapidly progressive glomerulonephritis 10.0 ACE NPPA
47 cetp-related hyperalphalipoproteinemia 10.0 ACE AGTR1
48 mixed germ cell-sex cord neoplasm 10.0 ACE AGTR1 REN
49 cervix small cell carcinoma 10.0 ACE AGTR1 REN
50 pulmonary neuroendocrine tumor 10.0 MEN1 POMC

Comorbidity relations with Hyperaldosteronism via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Hyperaldosteronism:



Diseases related to Hyperaldosteronism

Symptoms & Phenotypes for Hyperaldosteronism

MGI Mouse Phenotypes related to Hyperaldosteronism:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10 ACE AGTR1 CYP11B1 CYP11B2 KCNJ5 MEN1
2 growth/size/body region MP:0005378 9.76 ACE AGTR1 CYP11B1 CYP11B2 MEN1 NR3C2
3 homeostasis/metabolism MP:0005376 9.7 CYP17A1 MEN1 NPPA NR3C2 POMC REN
4 renal/urinary system MP:0005367 9.28 ACE AGTR1 CYP11B1 CYP11B2 NPPA NR3C2

Drugs & Therapeutics for Hyperaldosteronism

Drugs for Hyperaldosteronism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2 51-43-4 5816
3
Captopril Approved Phase 4 62571-86-2 44093
4
Spironolactone Approved Phase 4,Phase 3 1952-01-7, 52-01-7 5833
5
Eplerenone Approved Phase 4,Phase 3 107724-20-9 150310 443872
6
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
7
Losartan Approved Phase 4 114798-26-4 3961
8 insulin Phase 4
9 diuretics Phase 4,Phase 3
10 Dopamine agonists Phase 4
11
protease inhibitors Phase 4,Phase 2
12 Mydriatics Phase 4,Phase 3,Phase 2
13 Adrenergic Agents Phase 4,Phase 3,Phase 2
14 Natriuretic Agents Phase 4,Phase 3
15 Adrenergic Agonists Phase 4,Phase 3,Phase 2
16 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
17 Adrenergic beta-Agonists Phase 4,Phase 3,Phase 2
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
19 HIV Protease Inhibitors Phase 4,Phase 2
20 Hormone Antagonists Phase 4,Phase 2,Phase 3
21 Hormones Phase 4,Phase 3,Phase 2
22 Diuretics, Potassium Sparing Phase 4,Phase 3
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
24 Dopamine Agents Phase 4
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3
26 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2
27 Angiotensin-Converting Enzyme Inhibitors Phase 4
28 Epinephryl borate Phase 4,Phase 3,Phase 2
29 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2
30 Insulin, Globin Zinc Phase 4
31 Antihypertensive Agents Phase 4
32 Racepinephrine Phase 4,Phase 3,Phase 2
33 Respiratory System Agents Phase 4,Phase 3,Phase 2
34 Mineralocorticoid Receptor Antagonists Phase 4,Phase 3
35 Mineralocorticoids Phase 4,Phase 3,Phase 2
36 Autonomic Agents Phase 4,Phase 3,Phase 2
37 Bronchodilator Agents Phase 4,Phase 3,Phase 2
38 Antiparkinson Agents Phase 4
39
Angiotensin II Phase 4 68521-88-0, 11128-99-7 65143 172198
40 Coagulants Phase 4
41 Angiotensin II Type 1 Receptor Blockers Phase 4
42 Angiotensin Receptor Antagonists Phase 4
43 Angiotensinogen Phase 4
44 Anti-Arrhythmia Agents Phase 4
45 Fertility Agents Phase 4
46 Kallikreins Phase 4
47
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754 657311
48
Lidocaine Approved, Vet_approved Phase 2, Phase 3 137-58-6 3676
49
glycyrrhetinic acid Phase 2, Phase 3 471-53-4 18526330
50 beta-endorphin Phase 3

Interventional clinical trials:

(show top 50) (show all 65)
id Name Status NCT ID Phase
1 Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Unknown status NCT02127840 Phase 4
2 The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism Unknown status NCT00451672 Phase 4
3 Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Unknown status NCT00553722 Phase 4
4 Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism Completed NCT00155064 Phase 4
5 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
6 Aldosterone Antagonism and Microvascular Function Recruiting NCT01887119 Phase 4
7 SPARTACUS: Subtyping Primary Aldosteronism: a Randomized Trial Comparing Adrenal Vein Sampling and Computed Tomography Scan. Completed NCT01096654 Phase 3
8 The Role of Mineralocorticoid Receptors in Vascular Function Completed NCT00759525 Phase 2, Phase 3
9 Effectiveness of Eplerenone to Improve Target Organ Damage in Patients With Resistant Arterial Hypertension Completed NCT00138944 Phase 3
10 Effect of Eplerenone on Endothelial Function in Metabolic Syndrome Completed NCT01319344 Phase 3
11 Dynamic Hormone Diagnostics in Endocrine Disease Not yet recruiting NCT02934399 Phase 2, Phase 3
12 Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism Completed NCT00732771 Phase 2
13 Open-label Study on Treatment of Primary Aldosteronism With Everolimus Recruiting NCT03174171 Phase 2
14 Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy Active, not recruiting NCT01867710 Phase 2
15 Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates. Active, not recruiting NCT02025010 Phase 2
16 Postoperative Cardiovascular Index Change of Primary Aldosteronism Unknown status NCT00746070
17 Prevalence of Primary Aldosteronism in Hypertensive Patients Presenting With Atrial Flutter or Fibrillation Unknown status NCT01267747
18 Metabolic Syndrome and Insulin Resistance in Primary Aldosteronism Unknown status NCT00173082
19 Diagnostic Properties of Aldosterone-Renin Ratio in Primary Aldosteronism Among Hypertensives. Unknown status NCT00407784
20 Diagnosis of Primary Aldosteronism: Comparison of Post Captopril Active Renin Concentration and Plasma Renin Activity Unknown status NCT00917345
21 D2 Dopamine Receptor on Human Aldosterone-Producing Adenoma and Its Role in Aldosterone Secretion and Cell Proliferation Unknown status NCT00173446
22 Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome Unknown status NCT01021280
23 Optimizing Diagnosis Of Primary Aldosteronism Completed NCT02755519
24 Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism Completed NCT02938910
25 The Effect of Disease-specific Treatment on Bone Turnover Markers in Patients With Primary Aldosteronism Completed NCT02216721
26 Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment Completed NCT01728493
27 Intraoperative Analysis of Cortisol During Adrenal Vein Sampling Completed NCT01761344
28 Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism Completed NCT00004354
29 Natural History of Apparent Mineralocorticoid Excess Syndrome Completed NCT00474942
30 Adrenal Vein Sampling International Study (AVIS Study) Completed NCT01234220
31 Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China Completed NCT01459042
32 Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment Completed NCT01897727
33 Arterial Stiffness Index as a Predictor of Surgically Correctable Primary Aldosteronism Completed NCT01190501
34 Effects of Salt Intake on the Nervous Systems of Patients With Salt-Sensitive High Blood Pressure Completed NCT00001176
35 Diagnosis/Pathophysiology of Glucocorticoid Remediable Aldosteronism Hypertension Completed NCT00005394
36 Cardiovascular Evaluation of Adult PHA 1 Patients Completed NCT00646828
37 Aldosterone, Microvascular Function and Salt-sensitivity Completed NCT02068781
38 Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV Completed NCT01407237
39 Spironolactone to Decrease Potassium Wasting in Hypercalciurics on Thiazides Diuretics Completed NCT00276289
40 Primary Aldosteronism In Hypertensive Patients in China Recruiting NCT03155139
41 Primary Aldosteronism in Western Norway Recruiting NCT02832388
42 Screening for Primary Aldosteronism in a Population of Patients With Hypertension Recruiting NCT03105531
43 Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism Recruiting NCT03174847
44 Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas Recruiting NCT02362308
45 Renal Sympathetic Denervation From The Adventitia on Hypertension Recruiting NCT02642445
46 Plasma Aldosterone Levels and Atrial Fibrillation Reduction (ALDO-AF Study) Recruiting NCT02804321
47 Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate Recruiting NCT01858441
48 Omics Signature in the Diagnosis of Hypertension Recruiting NCT02772315
49 The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension Recruiting NCT01996449
50 Adrenal Tumors - Pathogenesis and Therapy Recruiting NCT00669266

Search NIH Clinical Center for Hyperaldosteronism

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Hyperaldosteronism

Genetic tests related to Hyperaldosteronism:

id Genetic test Affiliating Genes
1 Hyperaldosteronism 29

Anatomical Context for Hyperaldosteronism

MalaCards organs/tissues related to Hyperaldosteronism:

39
Adrenal Gland, Testes, Kidney, Heart, Pituitary, Cortex, Adrenal Cortex

Publications for Hyperaldosteronism

Articles related to Hyperaldosteronism:

(show top 50) (show all 567)
id Title Authors Year
1
Disordered zonal and cellular CYP11B2 enzyme expression in familial hyperaldosteronism type 3. ( 27793677 )
2017
2
Case Report: Nodule Development From Subcapsular Aldosterone-Producing Cell Clusters Causes Hyperaldosteronism. ( 26580238 )
2016
3
Cardiac Structure and Function in Hyperaldosteronism. ( 27307553 )
2016
4
Evaluation of a Recently Established Test for Familial Hyperaldosteronism Type 1. ( 27923252 )
2016
5
Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease. ( 27442639 )
2016
6
Hyperaldosteronism: How to Discriminate Among Different Disease Forms? ( 27136934 )
2016
7
Genetics of primary hyperaldosteronism. ( 27485459 )
2016
8
Primary hyperaldosteronism: a case of unilateral adrenal hyperplasia with contralateral incidentaloma. ( 27417992 )
2016
9
A Woman with Normotensive Primary Hyperaldosteronism. ( 26997605 )
2016
10
Hypertension Cure Following Laparoscopic Adrenalectomy for Hyperaldosteronism is not Universal: Trends Over Two Decades. ( 27872977 )
2016
11
[OP.3D.04] ACTIVATED CD4+ AND CD8+ T-CELL SUBPOPULATIONS IN PATIENTS WITH PRIMARY HYPERALDOSTERONISM AND TRUE RESISTANT HYPERTENSION. ( 27508670 )
2016
12
Hyperaldosteronism: Screening and Diagnostic Tests. ( 26971505 )
2016
13
A novel phenotype of familial hyperaldosteronism type III: Concurrence of aldosteronism and Cushing's syndrome. ( 27403928 )
2016
14
Surgical treatment of posterior nutcracker syndrome presented with hyperaldosteronism. ( 26892192 )
2016
15
Central serous chorioretinopathy in primary hyperaldosteronism. ( 27393297 )
2016
16
Histopathological classification of cross-sectional image negative hyperaldosteronism. ( 27967304 )
2016
17
Interrelationship Between Vitamin D Insufficiency, Calcium Homeostasis, Hyperaldosteronism, and Autoimmunity. ( 27097975 )
2016
18
Hyperaldosteronism induces left atrial systolic and diastolic dysfunction. ( 27614224 )
2016
19
Hyperaldosteronism after decreased renal K+ excretion in KCNMB2 knockout mice. ( 26962098 )
2016
20
KCNK3 Variants Are Associated With Hyperaldosteronism and Hypertension. ( 27296998 )
2016
21
Primary hyperaldosteronism diagnosed with adrenal vein sampling. Characteristics and follow-up after adrenalectomy in a Danish study. ( 26471096 )
2015
22
Resolution of Hyperreninemia, Secondary Hyperaldosteronism, and Hypokalemia With 177Lu-DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy in a Patient With Pancreatic Neuroendocrine Tumor. ( 26359564 )
2015
23
Netherton Syndrome in a Neonate with Possible Growth Hormone Deficiency and Transient Hyperaldosteronism. ( 26229701 )
2015
24
6C.03: A CASE OF SEVERE HYPERALDOSTERONISM CAUSED BY A DE NOVO KCNJ5 MUTATION. ( 26102935 )
2015
25
Pure aldosterone-secreting adrenocortical carcinoma in a patient with refractory primary hyperaldosteronism. ( 26273475 )
2015
26
Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension. ( 26238446 )
2015
27
NCI-H295R cell line as in vitro model of hyperaldosteronism lacks functional KCNJ5 (GIRK4; Kir3.4) channels. ( 25998841 )
2015
28
Iatrogenic myxoedema madness following radioactive iodine ablation for Graves' disease, with a concurrent diagnosis of primary hyperaldosteronism. ( 26525086 )
2015
29
An Association of Chronic Hyperaldosteronism with Medullary Nephrocalcinosis. ( 26413177 )
2015
30
Laparoendoscopic single-site adrenalectomy in patients with primary hyperaldosteronism: A prospective study with long-term follow up. ( 26626099 )
2015
31
An Update on Familial Hyperaldosteronism. ( 26445452 )
2015
32
Diagnostic Performance of Multidetector Computed Tomography in Distinguishing Unilateral From Bilateral Abnormalities in Primary Hyperaldosteronism: Comparison of Multidetector Computed Tomography With Adrenal Vein Sampling. ( 25594382 )
2015
33
Cardiovascular Risk in Primary Hyperaldosteronism. ( 26575306 )
2015
34
Incidental and Intentional Medicine Achieve SimilarA Results in Primary Hyperaldosteronism. ( 26193964 )
2015
35
Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype. ( 26252618 )
2015
36
Different potencies of angiotensin receptor blockers at suppressing adrenal I^-Arrestin1-dependent post-myocardial infarction hyperaldosteronism. ( 25541135 )
2014
37
Hyperaldosteronism and its association with hypotension and azotaemia in canine babesiosis. ( 25347616 )
2014
38
Long-term blood pressure control in patients undergoing adrenalectomy for primary hyperaldosteronism. ( 25456918 )
2014
39
A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical 'salt bridge' Kir3.4 residue. ( 25322277 )
2014
40
Pregnancy normalized familial hyperaldosteronism type I: a novel role for progesterone? ( 24943290 )
2014
41
Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism. ( 25036270 )
2014
42
Discordant genotype-phenotype correlation in familial hyperaldosteronism type III with KCNJ5 gene mutation: a patient report and review of the literature. ( 24819081 )
2014
43
Is adrenal venous sampling mandatory before surgical decision in case of primary hyperaldosteronism? ( 24481990 )
2014
44
Hyperaldosteronism: diagnosis, lateralization, and treatment. ( 24857581 )
2014
45
4-Hydroxychalcone attenuates hyperaldosteronism, inflammation, and renal injury in cryptochrome-null mice. ( 25003119 )
2014
46
Gender differences in anxiety and depressive symptoms in patients with primary hyperaldosteronism: A cross-sectional study. ( 22568586 )
2014
47
Neuroblastoma accompanied by hyperaldosteronism. ( 25340174 )
2014
48
Outcomes of adrenalectomy in patients with primary hyperaldosteronism - a single centre experience. ( 25471827 )
2014
49
A single-step approach to the diagnosis of primary hyperaldosteronism: filling a true void or burdening the bottleneck of adrenal vein sampling? ( 24853532 )
2014
50
A retrospective study of laparoscopic unilateral adrenalectomy for primary hyperaldosteronism caused by unilateral adrenal hyperplasia. ( 24488149 )
2014

Variations for Hyperaldosteronism

Expression for Hyperaldosteronism

Search GEO for disease gene expression data for Hyperaldosteronism.

Pathways for Hyperaldosteronism

GO Terms for Hyperaldosteronism

Biological processes related to Hyperaldosteronism according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 steroid metabolic process GO:0008202 9.73 CYP11B1 CYP11B2 CYP17A1
2 kidney development GO:0001822 9.7 ACE AGTR1 REN
3 regulation of vasoconstriction GO:0019229 9.57 ACE AGTR1
4 beta-amyloid metabolic process GO:0050435 9.55 ACE REN
5 regulation of vasodilation GO:0042312 9.54 ACE AGTR1
6 steroid biosynthetic process GO:0006694 9.54 CYP11B1 CYP11B2 CYP17A1
7 angiotensin maturation GO:0002003 9.51 ACE REN
8 C21-steroid hormone biosynthetic process GO:0006700 9.49 CYP11B1 CYP11B2
9 regulation of blood vessel diameter GO:0097746 9.48 ACE AGTR1
10 glucocorticoid biosynthetic process GO:0006704 9.46 CYP11B1 CYP17A1
11 cellular response to potassium ion GO:0035865 9.43 CYP11B1 CYP11B2
12 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.4 ACE AGTR1
13 renin-angiotensin regulation of aldosterone production GO:0002018 9.32 AGTR1 REN
14 aldosterone biosynthetic process GO:0032342 9.26 CYP11B1 CYP11B2
15 cortisol biosynthetic process GO:0034651 9.16 CYP11B1 CYP11B2
16 sterol metabolic process GO:0016125 9.13 CYP11B1 CYP11B2 CYP17A1
17 regulation of blood pressure GO:0008217 9.02 ACE CYP11B1 NPPA POMC REN

Molecular functions related to Hyperaldosteronism according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 iron ion binding GO:0005506 9.54 CYP11B1 CYP11B2 CYP17A1
2 heme binding GO:0020037 9.5 CYP11B1 CYP11B2 CYP17A1
3 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.43 CYP11B1 CYP11B2 CYP17A1
4 bradykinin receptor binding GO:0031711 9.16 ACE AGTR1
5 corticosterone 18-monooxygenase activity GO:0047783 8.96 CYP11B1 CYP11B2
6 steroid 11-beta-monooxygenase activity GO:0004507 8.62 CYP11B1 CYP11B2

Sources for Hyperaldosteronism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....